论文部分内容阅读
目的探讨格列美脲联合阿卡波糖治疗2型糖尿病(T2DM)临床疗效。方法选择确诊为T2DM患者50例,采用格列美脲联合阿卡波糖治疗,治疗12周,观察空腹血糖(FPG)、餐后2小时血糖(2hPG)、糖化血红蛋白(HbA1c)、体重指数(BMI)、甘油三酯(TG)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)、谷丙转氨酶(ALT)、谷草转氨酶(AST)、血清肌酐(SCr)等指标以及低血糖事件发生率。结果患者经过12周治疗后,FPG、2hPG、HbA1c和TG指标均较治疗前有显著改善(P<0.05)。BMI、LDL-C、HDL-C、ALT、AST、SCr等指标治疗前后无明显变化(P>0.05)。治疗过程中的低血糖发生率为4%,所有患者均未出现严重的肝、肾功能损害。结论格列美脲联合阿卡波糖治疗T2DM安全、有效、方便,患者依从性好,临床效果显著。
Objective To investigate the clinical efficacy of glimepiride and acarbose in treatment of type 2 diabetes mellitus (T2DM). Methods Fifty patients with T2DM were selected and treated with glimepiride and acarbose for 12 weeks. The levels of fasting blood glucose (FPG), 2hPG, HbA1c and body mass index BMI, TG, LDL-C, HDL-C, ALT, SCr, Other indicators and the incidence of hypoglycemic events. Results After 12 weeks of treatment, FPG, 2hPG, HbA1c and TG were significantly improved (P <0.05). BMI, LDL-C, HDL-C, ALT, AST, SCr and other indicators before and after treatment did not change significantly (P> 0.05). The incidence of hypoglycemia in the course of treatment was 4%, and no severe hepatic or renal impairment occurred in all patients. Conclusion Glimepiride combined with acarbose in the treatment of T2DM is safe, effective and convenient. The patient compliance is good and the clinical effect is remarkable.